

Advanced Training Course according to the German Federal Law "Gentechnik-Sicherheitsverordnung" (GenTSV § 28)

<u>Course Director:</u> Reinhard Geßner, MD, PhD Deputy Director of Institut for Laboratory Medicine, Pathobiochemistry and Molecular Diagnostics Universitätsklinikum Giessen-Marburg

Program

Monday (morning session)

starting 08.15	Arrival and registration of participants; distribution of course materials	
08:45 – 09.30	 Welcome and Course Introduction Presentation of the course concept Risks linked to genetic engineering Introduction of regulations in the USA and in Germany Hierarchy of European and German regulations Position statements by the ZKBS 	R. Geßner, MD, PhD Deputy Director Institut for Laboratory Medicine, Pathobiochemistry and MolecularDiagnostics Universitätsklinikum Giessen-Marburg
09:30 – 10.15	 Introduction to the German Genetic Engineering Act (GenTG) Definitions used in German genetic engineering regulations Central Committee on Biological Safety (ZKBS) Biohazard risk reduction principle System of biosafety levels 1 to 4 	R. Geßner, MD, PhD Deputy Director Institut for Laboratory Medicine, Pathobiochemistry and MolecularDiagnostics Universitätsklinikum Giessen-Marburg
10.15 - 10.30	Coffee Break	
10.30 - 11.15	 German Federal Regulations on Genetic Engineering Structure, legal definitions and interpretation of German laws European regulations of genetic engineering Application of the regulations in a genetic engineering facilities Regulations that are directly related to the Genetic Engineering Act 	W. Pellnitz, Med.Dir. a.D. Former Head of Dept. I C, Berlin State Office of Health and Social Affairs (LAGeSo) Berlin
11.15 – 12.00	 Genetic Engineering Act (GenTG) Announcement, registration and licensing of genetic engineering facilities and projects Controlled release of GMO and placing on the market Confidentiality of information provided to the authorities Decision process of the permit authority Public participation process Liabilities, fines and penalties 	W. Pellnitz, Med.Dir. a.D. Former Head of Dept. I C, Berlin State Office of Health and Social Affairs (LAGeSo)
12.00 –13.00	Microbial Infections - Routes of infection with viruses, bacteria and parasites - Pathogenesis and epidemiology - Immunological aspects including vaccination - Preventive measures and therapy	Prof. H. Zeichhardt, PhD Institute for Quality Validation in Viral Disease Diagnostics - (IQVD), Berlin or: HP. Grunert, PhD Biotechnological Diagnostics

Corporation (GBD), Berlin

Monday (afternoon session)

14.15 – 15.45	 Construction, Equipment and Maintenance of Genetic Engineering Facilities Requirements according to the German Genetic Engineering Safety Regulations Practical approach to fulfill the requirements when building and operating a genetic engineering facility 	R. Geßner, MD, PhD Deputy Director Institut for Laboratory Medicine, Pathobiochemistry and MolecularDiagnostics Universitätsklinikum Giessen-Marburg
15.45 – 16.00	Coffee Break	
16.00 17.00	Sterilization, Disinfection, Inactivation - Sterilization by physical procedures - Surface disinfection - Hand disinfection	R. Geßner, MD, PhD Institute of Clinical Chemistry, Hannover Medical University (MHH)
17.00 – 18.00	 Genetically Modified Plants Risk assessment Biosafety classification Environmental considerations upon conducting deliberate controlled release experiments Placing on the market of genetically modified plants 	Th. Pickardt, PhD Institute of Applied Genetics Free University of Berlin
18.00 - 20.00	Networking and Refreshments	

Tuesday (morning session)

08.30 – 09.15	Occupational Safety Aspects in Genetic Engineering - Occupational Safety Regulations - Federal Immission Control Act	W. Pellnitz, Med.Dir. a.D. Former Head of Dept. I C, Berlin State Office of Health and Social Affairs (LAGeSo)
09.15 – 10:00	 Genetic Engineering Safety Regulation (GenTSV) Biosafety classification in laboratories, green houses and animal facilities Waste and waste water of genetic engineering facilities Responsibilities of the operator, the project leader and the biological safety officer Penalties 	W. Pellnitz, Med.Dir. a.D. Former Head of Dept. I C, Berlin State Office of Health and Social Affairs (LAGeSo)
10.00 - 10.15	Coffee Break	
10.15 - 11.00	Other Federal Regulation Applying to Genetic Engineering - Bioweapon Convention - Infection Prevention Act - Animal Epidemia Protection Act and Animal Infectious Agents Regulation - Animal Protection Act	W. Pellnitz, Med.Dir. a.D. Former Head of Dept. I C, Berlin State Office of Health and Social Affairs (LAGeSo)
11.00 – 11.45	 Additional Regulations Applying to the Genetic Engineering Facility Chemical hazards in the genetic engineering facility (GefStoffV) Radiation protection upon using radionuclide-labeled GMO (StrlSchV) 	R. Geßner, MD, PhD Deputy Director Institut for Laboratory Medicine, Pathobiochemistry and MolecularDiagnostics Universitätsklinikum Giessen-Marburg
11.45 – 13.00	Lunch Break	
	Tuesday (afternoom session)	
13.00 – 14.30	 Organizational Safety Measures, Processing of Applications and Case Presentations Biological risk assessment and biosafety classification Announcement, registration and licensing of genetic engineering facilities and projects Access to and designation of genetic engineering facilities Disinfection directory, emergency plan and operating instruction Recording of experiments with GMO Surveillance of genetic engineering facilities 	P. Witkowski, PhD Head of Genetic Engineering Unit, Berlin State Office of Health and Social Affairs (LAGeSo)
14.30 – 14.45	Coffee Break	
14.45 – 16.15	 Risk assessment and biosafety classification Safety aspects when working with GMO Risk potential of common donor and acceptor organisms Risk potential of common cloning and expression systems Biosafety classification of genetic engineering projects involving different organisms and vectors Biological safety measures 	M. Kaspari, PhD Federal Office of Consumer Protection and Food Safety (BVL), Berlin
16.15 - 17.00	Final discussion: case studies and trouble shooting - Risk assessment of genetic engineering projects	R. Geßner, MD, PhD P. Witkowski, PhD

Risk assessment of genetic engineering projects
 Practical applications using case studies that are either provided or may be proposed by the participants
 P. Witkowski, Pr
 M. Kaspari, PhD